ES2681996R1 - Composiciones para reducir el apetito y el ansia,potenciar la saciedad, mejorar el estado de animo y reducir el estres. - Google Patents

Composiciones para reducir el apetito y el ansia,potenciar la saciedad, mejorar el estado de animo y reducir el estres. Download PDF

Info

Publication number
ES2681996R1
ES2681996R1 ES201830028A ES201830028A ES2681996R1 ES 2681996 R1 ES2681996 R1 ES 2681996R1 ES 201830028 A ES201830028 A ES 201830028A ES 201830028 A ES201830028 A ES 201830028A ES 2681996 R1 ES2681996 R1 ES 2681996R1
Authority
ES
Spain
Prior art keywords
reduce
appetite
compositions
noratiriol
mangiferin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201830028A
Other languages
English (en)
Other versions
ES2681996B2 (es
ES2681996A2 (es
Inventor
Miguel JIMÉNEZ DEL RÍO
Julia C. WIEBE
Laura LOPÉZ RÍOS
Tanausú VEGA MORALES
Rubén PÉREZ MACHÍN
Álvaro SÁNCHEZ RODRÍGUEZ
Carlos J. MATEOS
Nigel Peter Gericke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektium Pharma SL
Original Assignee
Nektium Pharma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektium Pharma SL filed Critical Nektium Pharma SL
Publication of ES2681996A2 publication Critical patent/ES2681996A2/es
Publication of ES2681996R1 publication Critical patent/ES2681996R1/es
Application granted granted Critical
Publication of ES2681996B2 publication Critical patent/ES2681996B2/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/89—Cyperaceae (Sedge family)
    • A61K36/8905—Cyperus (flatsedge)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Composiciones para reducir el apetito y el ansia, potenciar la saciedad, mejorar el estado de ánimo y reducir el estrés.#Una composición que comprende:#a) una cantidad eficaz de un extracto de piel de Cyperus esculentus, rizomas de Cyperus esculentus, o una combinación de los mismos;#b) una cantidad eficaz de mangiferina, noratiriol, o un extracto que comprende mangiferina o noratiriol; o#c) una combinación sinérgica de (a) y (b);#para su uso en la potenciación de al menos uno de reducción del ansia, mejora del estado de ánimo, evitación de la depresión, prevención de aumento de peso tras pérdida de peso a partir de dieta, reducción de efectos secundarios negativos producidos por fármacos que reducen el apetito y dejar de fumar y ayuda de envejecimiento saludable en una persona que lo necesita. La composición para su uso puede comprender un tercer principio activo en combinación con el extracto de Cyperus esculentus y mangiferina o noratiriol.
ES201830028A 2017-01-10 2018-01-10 Composiciones para reducir el apetito y el ansia,potenciar la saciedad, mejorar el estado de animo y reducir el estres. Expired - Fee Related ES2681996B2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/402,886 2017-01-10
US15/402,886 US10874708B2 (en) 2017-01-10 2017-01-10 Compositions for reducing appetite and craving, increasing satiety, enhancing mood, and reducing stress

Publications (3)

Publication Number Publication Date
ES2681996A2 ES2681996A2 (es) 2018-09-17
ES2681996R1 true ES2681996R1 (es) 2018-09-20
ES2681996B2 ES2681996B2 (es) 2020-06-02

Family

ID=60972226

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201830028A Expired - Fee Related ES2681996B2 (es) 2017-01-10 2018-01-10 Composiciones para reducir el apetito y el ansia,potenciar la saciedad, mejorar el estado de animo y reducir el estres.

Country Status (9)

Country Link
US (2) US10874708B2 (es)
EP (1) EP3568130A1 (es)
JP (1) JP2020504153A (es)
KR (1) KR102480206B1 (es)
CN (1) CN110402138A (es)
BR (1) BR112019014238A2 (es)
CA (1) CA3049908A1 (es)
ES (1) ES2681996B2 (es)
WO (1) WO2018130549A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11376294B2 (en) 2016-07-19 2022-07-05 Nektium Pharma S.L. Mangiferin-containing compositions for improving sports performance
WO2020250224A1 (en) * 2019-06-11 2020-12-17 B.T. Sweet Ltd Botanical sugar substitute
CN110292547B (zh) * 2019-08-08 2022-03-11 广东丸美生物技术股份有限公司 化妆品组合物及其制备方法和具有抗蓝光作用的化妆品
CN111466908B (zh) * 2020-04-09 2022-08-09 瘦声(杭州)科技有限公司 一种利用eeg筛选可影响食欲音频的方法
KR102282491B1 (ko) * 2020-10-26 2021-07-27 주식회사 에스앤케이바이오텍 탄수화물 함량이 저감된 탄수화물 음식의 제조방법
KR102269586B1 (ko) * 2020-11-10 2021-06-24 농업회사법인 주식회사 오케이120 식욕 조절 및 체중 감량 목적의 다이어트용 사탕
JP2022097984A (ja) * 2020-12-21 2022-07-01 富士フイルム株式会社 精神状態改善剤
KR102255693B1 (ko) 2021-02-22 2021-05-25 주식회사 인화무역 시서스의 재배방법
CA3211601A1 (en) * 2021-03-09 2022-09-15 Jr. Darrell Eugene Holton Oral products and methods of manufacture
CN113341050B (zh) * 2021-04-28 2023-05-02 内蒙古大学 一种油莎草地上部分多种成分的液质定量方法及其应用
CN115137066A (zh) * 2022-05-31 2022-10-04 澳美制药(苏州)有限公司 一种减肥片剂及其制备方法
AU2023311967A1 (en) * 2022-07-19 2025-02-06 Pinata Holdings Inc. Inhalable serotonin receptor agonist formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985282A (en) * 1997-01-22 1999-11-16 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
KR20060034405A (ko) * 2004-10-19 2006-04-24 대구한의대학교산학협력단 니코틴 중독 및 금단증상의 예방 및 치료를 위한 산조인추출물을 함유하는 조성물
EP2397039A1 (en) * 2010-06-21 2011-12-21 Abbott Laboratories Compositions for delaying progression of diabetes using Salacia oblonga extract

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2082170B (en) 1980-07-16 1984-03-28 Vnii Lekarstvenny Process for preparing mangiferin
US4436732A (en) 1981-10-26 1984-03-13 Vichkanova Serafima A Medicated compound for treating diseases infected by virus of the herpes group
ES2111500B1 (es) 1996-08-22 1998-07-16 Coret Monros Salvador Proceso para la obtencion de una composicion alimenticia a base de chufa y platano.
US5798101A (en) * 1997-01-22 1998-08-25 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
CA2359057C (en) 1999-11-12 2010-10-12 K. M. Slimak Use of tropical root crops in effective intervention strategies for treating difficult and complex cases and chronic diseases
AU4515701A (en) 1999-12-02 2001-06-18 Interlab, Inc. Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins
RU2176516C1 (ru) 2000-11-17 2001-12-10 Чернов Юрий Николаевич Адаптоген стресс-корректор
RU2197259C1 (ru) 2001-07-18 2003-01-27 Чернов Юрий Николаевич Антидиабетическое средство
ES2277567B1 (es) * 2005-12-30 2008-06-01 Universidad Del Pais Vasco Compuestos con propiedades neuroprotectoras.
CN101003558A (zh) 2006-10-17 2007-07-25 中国人民解放军第二军医大学 芒果苷类化合物以及其制备方法和在医药领域的应用
WO2008061480A1 (en) 2006-11-24 2008-05-29 Hainan Deze Drug Research Co., Ltd Novel mangiferin calcium salts, the method for its preparation and its use
JP5529745B2 (ja) 2007-11-22 2014-06-25 ハイナン ディーズ ドラッグ リサーチ コーポレーション リミテッド 新規なマンゴー配糖体カルシウム塩、その製造方法及びその使用
CN101848922B (zh) 2007-11-22 2013-01-02 海南德泽药物研究有限公司 一种新的芒果苷钙盐及其制备方法与用途
FR2926726B1 (fr) 2008-01-28 2010-04-02 Limousine D Applic Biolog Dite Utilisation d'un actif issu de cyperus esculentus pour son action anti-age.
FR2929945B1 (fr) 2008-04-11 2010-09-03 Inst Rech Developpement Ird Procede d'extraction de mangiferine et d'isomanfigerine.
CN101270230B (zh) 2008-05-20 2012-06-20 贺州学院 一种超声波辅助提取荸荠皮天然棕色素的方法
CN101269161B (zh) 2008-05-20 2011-12-07 贺州学院 一种从荸荠皮中提取总黄酮的工艺
GB2464700B (en) 2008-10-22 2012-11-28 Univ Plymouth A method of colouring tin and tin-containing articles
CN101732360B (zh) 2008-11-14 2011-09-07 郑州豫密药业股份有限公司 中药丸剂的打光方法
CN101921270A (zh) 2009-06-16 2010-12-22 海南德泽药物研究有限公司 一种芒果苷小檗碱盐及其制备方法与用途
CN101731710B (zh) 2010-01-17 2012-11-28 李国平 一种油莎豆饮料及其制作方法
CN103191141B (zh) 2012-01-05 2014-10-22 昆明制药集团股份有限公司 3-甲氧基芒果苷在制备治疗脑卒中后抑郁药物中的应用
US9198943B2 (en) * 2012-07-12 2015-12-01 Michael Parker Jones Silene capensis for inhibiting cravings
CN102920696B (zh) 2012-09-27 2015-03-18 戴好富 芒果苷类化合物或芒果提取物用作胰脂肪酶抑制剂、制备防治肥胖的药物或食品的应用
US20140220220A1 (en) 2013-02-05 2014-08-07 Nutso, Llc Tiger nut foodstuff and systems and methods for processing tiger nut foodstuffs
CN104558070B (zh) 2013-10-14 2017-10-24 北京大学 新芒果苷的化学合成方法及中间体化合物
KR20160078507A (ko) * 2013-11-19 2016-07-04 옴니액티브 헬스 테크놀로지스 (캐나다) 리미티드 살라시아 조성물, 이들의 투여에 의한 치료방법 및 이들의 제조방법
CN103877014A (zh) * 2014-03-26 2014-06-25 邓家刚 一种芒果苷口服液及其制备方法
CN104083571B (zh) * 2014-07-29 2017-03-29 新疆大学 一种有增强微循环作用的油莎草总黄酮的提取方法及应用
EP3009138B8 (en) * 2014-09-01 2019-06-26 Vidya Herbs Pvt Ltd Mangifera extract for the management of obesity and/or weight
US10537604B2 (en) 2016-07-19 2020-01-21 Nektium Pharma, S.L. Compositions for enhancing brain activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985282A (en) * 1997-01-22 1999-11-16 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
KR20060034405A (ko) * 2004-10-19 2006-04-24 대구한의대학교산학협력단 니코틴 중독 및 금단증상의 예방 및 치료를 위한 산조인추출물을 함유하는 조성물
EP2397039A1 (en) * 2010-06-21 2011-12-21 Abbott Laboratories Compositions for delaying progression of diabetes using Salacia oblonga extract

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DEVON L J. "Tiger nuts: This silly-named superfood was used by humans over a million years ago". NaturalNews.com [online], 16/03/2016, [en línea][recuperado el 06/09/2018]. Recuperado de Internet (URL:https://www.naturalnews.com/053288_superfoods_tiger_nuts_breast_milk.html#), todo el documento; en particular, 5º párrafo, página 2. *

Also Published As

Publication number Publication date
CA3049908A1 (en) 2018-07-19
ES2681996B2 (es) 2020-06-02
BR112019014238A2 (pt) 2020-08-18
US11141450B2 (en) 2021-10-12
KR102480206B1 (ko) 2022-12-21
US20190351000A1 (en) 2019-11-21
ES2681996A2 (es) 2018-09-17
WO2018130549A1 (en) 2018-07-19
US10874708B2 (en) 2020-12-29
KR20190104388A (ko) 2019-09-09
US20180193400A1 (en) 2018-07-12
CN110402138A (zh) 2019-11-01
EP3568130A1 (en) 2019-11-20
JP2020504153A (ja) 2020-02-06

Similar Documents

Publication Publication Date Title
ES2681996R1 (es) Composiciones para reducir el apetito y el ansia,potenciar la saciedad, mejorar el estado de animo y reducir el estres.
CL2019000268A1 (es) Composición de cannabis.
CL2021001609A1 (es) Régimen de dosificación y combinación farmacéutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
MX2018011348A (es) Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades.
CL2018001007A1 (es) Composiciones farmacéuticas para terapias combinadas (sol. divisional de n° 201702538).
CL2014001587A1 (es) Combinacion farmaceutica, composicion farmaceutica o kit farmaceutico que comprenden un inhibidor de dpp-4 y un analogo de glp-1; metodo para tratar y/o prevenir la obesidad o el sobrepesoo para reducir el peso corporal en un paciente humano.
MX391293B (es) DERIVADOs DE OXINTOMODULINA NOVEDOSOS Y COMPOSICION FARMACEUTICA PARA TRATAR LA OBESIDAD QUE COMPRENDE LOS MISMOS.
PA8849701A1 (es) Forma de dosificacion farmaceutica que comprende nifedipino o nisoldipino y un antagonista de anglotensina ii y/o un diuretico
AR107303A1 (es) Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
UY28862A1 (es) Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
MX2015014656A (es) Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas.
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
MX2019010594A (es) Beta-caseina a2 y prevencion de la inflamacion del intestino.
PY1454647A (es) Composiciones y métodos para reducir eventos adversos cardiovasculares graves
BR112018006368A2 (pt) composição para desempenho melhorado
CL2022003507A1 (es) Composición y método para tratar el dolor crónico
CL2016000544A1 (es) Composición cosmética que comprende 0,0001 a 10% en peso de extracto de guacatonga (casearia sylvestris) y 0,00005 a 10% en peso de extracto de aroeira (schinus terebinthifolius raddi) ambos respecto al peso total de la composición; uso de la composición en la prevención y/o tratamiento de los signos de envejicimiento de la piel; metodo para prevenir y/o tratar los signos de envejecimiento de la piel.
MX2016011667A (es) Composiciones topicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
CL2021003291A1 (es) Mezcla de extractos de plantas para su uso en la prevención y/o tratamiento de enfermedades inflamatorias crónicas del intestino.
PE20191149A1 (es) Uso farmaceutico de una composicion que contiene pirfenidona de liberacion prolongada (pfd-lp) para la reversion y tratamiento de la esteatohepatitis humana (nafld/nash)
WO2018025080A3 (en) Compositions for enhancing brain activity
MX344303B (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
CO2020004801A2 (es) Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares
BR112015019264A8 (pt) cápsulas para o tratamento de helicobacter pylori e seu uso".
CO2020005366A2 (es) Composición plaguicida que contiene tidiazurón y ácido poliglutámico

Legal Events

Date Code Title Description
BA2A Patent application published

Ref document number: 2681996

Country of ref document: ES

Kind code of ref document: A2

Effective date: 20180917

EC2A Search report published

Ref document number: 2681996

Country of ref document: ES

Kind code of ref document: R1

Effective date: 20180913

FG2A Definitive protection

Ref document number: 2681996

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20200602

FD2A Announcement of lapse in spain

Effective date: 20260226